Sam is a professional trader and the lead stock market news writer at AskTraders. After starting his career in the forex market, Sam now focuses on gold and stocks with a preference for fundamental and macroeconomic analysis.
Shares of AzurRX BioPharma (NASDAQ: AZRX) have surged premarket after the company reported positive topline results from its Phase 2 Combination Trial evaluating MS1819.
The trial evaluated MS1819 in combination with the current standard of care, porcine-derived pancreatic enzyme replacement therapy (PERT), to treat severe exocrine pancreatic insufficiency in patients with cystic fibrosis.
The company collected data from 20 patients and showed MS1819 in combination with PERT “led to clinically meaningful improvements in the primary efficacy endpoint, the Coefficient of Fat Absorption.”
AzurRx is now developing a new enteric-coated microbead formulation for MS1819 and plans to start a bridging study in 2022 evaluating the formulation as a single-agent therapy.
“This is a positive day for AzurRx, and with data from all 20 study participants in hand, our enthusiasm for the MS1819 program remains undiminished,” stated James Sapirstein, President and CEO of AzurRx.
“Topline data clearly show that combining MS1819 to the daily dose of PERT had clinical benefits for all patients and improved quality of life. Our next step with the MS1819 program is to finalize development of a new enteric-coated microbead formulation, which we believe will enable more of the medication to reach the small intestine thereby enhancing its therapeutic potential. Formulation work is expected to be completed prior to year-end,” added Sapirstein.
The company's shares have rallied 49.49% premarket to $0.7881 following Tuesday's 5% loss.
One of the most frequently asked questions we receive is, “what stocks are best to buy right now?” It's a wide-ranging question, but one that we have answered… Our AskTraders stock analysts regularly review the market and compile a list of which companies you should be adding to your portfolio, including short and longer-term positions. Here are the best stocks to buy right now
CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage . 75 % of retail investor accounts lose money when trading CFDs with this provider . You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money .